{
  "source": "PA-Notification-Entresto.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1167-14\nProgram Prior Authorization/Notification\nMedication Entresto® (valsartan-sacubitril)\nP&T Approval Date 5/2015, 6/2016, 6/2017, 6/2018, 6/2019, 11/2019, 4/2020, 4/2021, 4/2022,\n4/2023, 4/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nEntresto (valsartan-sacubitril) is indicated to reduce the risk of cardiovascular death and\nhospitalization for heart failure patients with chronic heart failure. Benefits are most clearly\nevident in patients with left ventricular ejection fraction (LVEF) below normal. It is also\nindicated for the treatment of symptomatic heart failure with systemic left ventricular systolic\ndysfunction in pediatric patients aged one year and older.\n2. Coverage Criteriaa:\nA. Authorization\n1. Entresto will be approved based on one of the following:\na. Diagnosis of chronic adult heart failure\n-OR-\nb. Diagnosis of pediatric heart failure with systemic left ventricular systolic dysfunction\nwhich is symptomatic.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply Limits may be in place.\n4. References:\n1. Entresto [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April\n2024.\nProgram Prior Authorization/Notification - Entresto (valsartan-sacubitril)\nChange Control\n5/2015 New program.\n10/2015 Administrative change to adjust program number.\n6/2016 Updated reference.\n6/2017 Annual review. No change",
    "tion/Notification - Entresto (valsartan-sacubitril)\nChange Control\n5/2015 New program.\n10/2015 Administrative change to adjust program number.\n6/2016 Updated reference.\n6/2017 Annual review. No changes.\n6/2018 Annual review. Updated reauthorization approval time period.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n6/2019 Annual review. Removed reauthorization criteria.\n11/2019 Added criteria for coverage of pediatric heart failure. Updated references.\n4/2020 Administrative update to remove “initial” from authorization criteria.\n4/2021 Updated to remove heart failure classification and ejection fraction\nrequirements based on updated labeling.\n4/2022 Annual review with no changes.\n4/2023 Annual review. Added state mandate footnote.\n4/2024 Annual review with no changes.\n5/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}